Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Status:
Completed
Trial end date:
2017-07-28
Target enrollment:
Participant gender:
Summary
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging
characteristics of flortaucipir in control subjects and patients with clinically defined MCI
and AD dementia (AD).